Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idarubicin + Cytarabine vs Cytarabine in Elderly AML Consolidation
NCT04216771Phase 3Unknown
- Sponsor
- Fujian Medical University
- Start
- Jan 2020
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of idarubicin in acute myeloid leukemia (AML), sponsored by Fujian Medical University. Status: unknown.
02
Drugs
idarubicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04216771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04216771.